Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Eye Diseases

Rare Diseases

Melanoma

Retinal Detachment

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Skin Diseases

Retinal Diseases

Intraocular Melanoma

Neuroendocrine Tumor

Neuroepithelioma

Anti-Inflammatory Agents

All Drugs and Chemicals

Triamcinolone

Triamcinolone Acetonide

Triamcinolone hexacetonide

Triamcinolone diacetate

Glucocorticoids

Hormones

Hormone Antagonists

Immunosuppressive Agents

Immunologic Factors

Enzyme Inhibitors

Transpupillary thermotherapy is performed as monotherapy. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. TTT could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid

transpupillary thermotherapy followed by an intravitreal injection of triamcinolone. It is performed with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor. After an intravitreal injection of triamcinolone was perfomed under sterile conditions. TTT and triamcinolone injection could be repeated at intervals of 6-8 weeks with the goal of achieving a complete resolution of fluid.

Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.

We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.

Transpupillary thermotherapy

Ira Seibel, MD

Proton beam therapy is a safe irradiation modality for choroidal melanoma. But often after irradiation the exudation increases resulting in an exudative retinal detachment requiring vitreoretinal surgery. It is known that intravitreally injected triamcinolone and TTT is capable to decrease the exudation. If there is any advantage in a combined treatment this study will investigate.

Proton beam therapy is an eye preserving irradiation modality for uveal melanoma. After proton beam therapy tumor related lipid exudation and exudative retinal detachment often increase. Therefore vitreoretinal surgery is sometimes required to reattach the retina to protect visual acuity. It is known that intravitreally injected triamcinolone and TTT is capable to decrease exudation. If there is any advantage in a combined treatment and if it is that effective to possibly avoid vitreoretinal surgery this study will investigate.

TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy

Transpupillary Thermotherapy (TTT) Alone Versus the Combined Therapy Consisting of TTT and Intravitreal Injection of Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy

If tumor relaxed lipid exudates or a neovascular glaucoma develop a secondary vitrectomy will be required to preserve the globe.

Charite University, Berlin, Germany

Combined treatment of Transpupillary Thermotherapy and ICG-based photodynamic therapy (PDT)

TTT + ICG-based PDT

Peter E Liggett, MD

This is a report of 10 years results of combined Transpupillary thermotherapy (TTT) treatment with Indocyanine green (ICG) in controlling small and medium-sized choroidal melanomas.

The study was done in a Clinical practice setting. Forty six eyes of 46 patients with small or medium-sized choroidal melanomas were treated with i-TTT using infrared light delivered from a diode laser. All patients were evaluated to rule out systemic metastasis and underwent a complete ophthalmological evaluation including: Slit lamp biomicroscopy, dilated fundus examination, Fluorescein angiography, Optical coherence tomography and A/B ultrasonography. Main outcome measures were: Changes in visual acuity, complications associated with the treatment and local control of the tumor.

Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma

10 Years Report of Combined Simultaneous Transpupillary Thermotherapy and ICG-based Photodynamic Therapy for Choroidal Melanoma

New England Retina Associates

Principal Investigator

Antineoplastic Agents

Ranibizumab

Angiogenesis Inhibitors

Growth Inhibitors

6 patients will receive 3 injections of Ranibizumab (2 mg) a month apart.

6 patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.

intravitreal injections of ranibizumab once a month, times 3.

Ranibizumab 2 mg

6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.

0.5 mg Ranibizumab

Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.

Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)

Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma

Genentech, Inc.

Adverse event data are not available to be reported per group or according to severity because the PI left the institution and adverse event data in the required format is not available.

patients will receive 3 injections of Ranibizumab (2 mg) a month apart.

Ranibizumab 2 mg: intravitreal injections of ranibizumab once a month, times 3.

High Dose Ranibizumab

patients will receive 0.5 mg of Ranibizumab every two weeks per 3 months.

0.5 mg Ranibizumab: 6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.

Standard Dose Ranibizumab

Total

Age, Categorical

Sex: Female, Male

Leslie Hurst- study coordinator

vascular occlusion

retinal detachment

persistent sub retinal fluid (srf)

metastatic death

complications were only assessed in the high dose group

To Evaluate the Safety/Efficacy of Intravitreal Injection of High Dose Ranibizumab Combined With TTT + ICG-based Photodynamic Therapy in the Treatment of Choroidal Melanoma by Reporting the Number of Participants With Complications.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
TTT Versus TTT and Triamcinolone to Decrease Exudation in Choroidal Melanoma After Proton Beam Therapy	NCT02379000	Exudative Retin... Uveal Melanoma	Triamcinolone A... Transpupillary ...	18 Years -	Charite University, Berlin, Germany
Long Term Results of Combined Transpupillary Thermotherapy (TTT) Indocyanine Green (ICG) Based Photodynamic Therapy (PDT) in Choroidal Melanoma	NCT01253759	Choroidal Melan...	TTT + ICG-based...	18 Years - 95 Years	New England Retina Associates
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)	NCT01251978	Choroidal Melan...	Ranibizumab 2 m... 0.5 mg Ranibizu...	50 Years - 90 Years	New England Retina Associates

Spots Global Cancer Trial Database for transpupillary thermotherapy